Evaluation of the effect of Familact synbiotic in treatment of community acquired pneumonia

Evaluation of the effect of Familact synbiotic on the outcomes of the patients with community acquired pneumonia (clinical improvement, laboratory and complications)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140623018206N2

Enrollment

130

Registered

2021-07-14

Start date

2021-07-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community acquired pneumonia. Pneumonia due to Streptococcus pneumoniae

Interventions

Intervention 1: Intervention group: Familact capsule (once daily) for 10 days along with antibiotics. Familact® is a synbiotic compound (probiotic + prebiotic) and it contains high amounts of 9 benefi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years old with community-acquired pneumonia diagnosed by an infectious disease specialist and requiring hospitalization (based on CURB-65 criteria) Patients with the same epidemiological factors (age, gender, and underlying disease) and possible microorganisms Patients who need one type of treatment and do not need to other treatment such as steroids

Exclusion criteria

Exclusion criteria: Patients who have taken antibiotics 48 hours before hospitalization Patients with immunodeficiency (HIV, receiving immunosuppressive drugs, transplantation, chemotherapy, acute pancreatitis), pregnant and lactating women Patients who have consumed probiotics, prebiotics and synbiotics in the past month Patients who have not consented

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: At first, after 72 hours, and at the end of hospitalization. Method of measurement: Thermometer.;Respiratory Rate. Timepoint: At first, after 72 hours, and at the end of hospitalization. Method of measurement: Respiratory Rate per minute.;White blood cells. Timepoint: After 72 hours of hospitalization. Method of measurement: Laboratory test.;Erythrocyte sedimentation rate. Timepoint: At first, and at the end of hospitalization. Method of measurement: Laboratory test.;C-Reactive Protein. Timepoint: At first, and at the end of hospitalization. Method of measurement: Laboratory test.	—

Measure

Time frame

Fever. Timepoint: At first, after 72 hours, and at the end of hospitalization. Method of measurement: Thermometer.;Respiratory Rate. Timepoint: At first, after 72 hours, and at the end of hospitalization. Method of measurement: Respiratory Rate per minute.;White blood cells. Timepoint: After 72 hours of hospitalization. Method of measurement: Laboratory test.;Erythrocyte sedimentation rate. Timepoint: At first, and at the end of hospitalization. Method of measurement: Laboratory test.;C-Reactive Protein. Timepoint: At first, and at the end of hospitalization. Method of measurement: Laboratory test.

—

Secondary

Measure	Time frame
Complications of pneumonia. Timepoint: At the end of study. Method of measurement: Questionnaire.;Duration of hospitalization. Timepoint: During the study. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Ebrahimzadeh

Birjand University of Medical Sciences

a.ebrahimzadeh@bums.ac.ir+98 56 1444 8671

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026